Amgen 1Q numbers - beat expectations

03-MAY-16

Amgen, one of the world's leading biotech companies reported results for their first quarter of the 2016 financial year on Thursday evening. This is not a company that we have owned for a long time, it is a relatively recent acquisition for our clients. In fact, we have only been buying this company for clients for around a year. The nearly four decade old company, as per their mission statement are involved in producing cost effective therapies that are based on advances in cellular and molecular biology. If you were not paying attention in those respective subjects, biology and chemistry, then I suppose like most of us without the advanced studies in the respective fields, we will have to understand what the therapies do, whether or not there will be greater need for them, whether or not the company is on the right track, whether or not importantly that the company is a good investment at this juncture.


Read more...

Amgen 4Q and full year numbers

01-FEB-16

Amgen reported numbers for the fourth quarter and full year last week Thursday, after the market closed. This stock is new to the recommended list, perhaps a refresher on what the business does is in order. The company treats serious illnesses, that includes cancer, kidney diseases, rheumatoid arthritis and bone diseases, primarily. The company uses (a lot of this is from their website) advanced human genetics to firstly understand the conditions, before researching and manufacturing at the highest possible standard.


Read more...

Amgen Q3 numbers

29-OCT-15

Amgen, one of the newest additions to the Vestact recommended stock stable, reported numbers post the market last evening. This is a company that I have been watching for about 8 years, back when Lehman Brothers still housed employees and actually had a family. The numbers were for Q3 and were a pretty solid beat, guidance was also a little higher than the previous range. Preliminary guidance was released for 2016 too, the group expects revenues in the region of 21.7 to 22.3 billion Dollars for that financial year, with EPS in the region of 10.35 to 10.75. The share price closed last evening at 162.67, in simple terms the share price trades in the middle of the guided range (10.55 USD EPS) on 15.4 times earnings. The yield at current levels is just below 2 percent.


Read more...

Older stories...

Newsletter Sign Up

Sign up for our free daily market newsletter.

Paul Theron's Tweets

Byron Lotter's Tweets

Michael Treherne's Tweets

Bright Khumalo's Tweets